• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

非转移性病理 T3a 期肾细胞癌患者术后无复发生存预测列线图的建立与验证。

Development and Validation of a Nomogram for Predicting Postoperative Recurrence-Free Survival in Patients With Nonmetastatic Pathological T3a Stage Renal Cell Carcinoma.

机构信息

Department of Urology, Air Force Medical Center, PLA, Air Force Medical University, Beijing, China; Department of Traditional Chinese Medicine, The Sixth Medical Centre, Chinese People's Liberation Army General Hospital, Beijing, China; Department of Urology, The Third Medical Centre, Chinese People's Liberation Army General Hospital, Beijing, China.

Department of Urology, The Third Medical Centre, Chinese People's Liberation Army General Hospital, Beijing, China.

出版信息

Clin Genitourin Cancer. 2024 Dec;22(6):102196. doi: 10.1016/j.clgc.2024.102196. Epub 2024 Aug 12.

DOI:10.1016/j.clgc.2024.102196
PMID:39276504
Abstract

BACKGROUND

To establish a nomogram predicting postoperative recurrence-free survival (RFS) in patients with nonmetastatic renal cell carcinoma (RCC) of pathological T3a (pT3a) stage undergoing nephrectomy.

MATERIALS AND METHODS

A retrospective review included 668 patients with pT3a RCC between 2008 and 2019, randomly divided into training and validation groups (7:3 ratio). Cox regression analysis established the RFS-predicting nomogram in the training group. Nomogram performance was assessed using Harrell's concordance index (C-index), time-dependent receiver operating characteristic curve, decision curve analysis, and Kaplan-Meier survival analysis.

RESULTS

Of the 668 patients with pT3a RCC, 167 patients experienced local recurrence or distant metastasis. Using multivariable Cox regression analysis, tumor size, ISUP grade, necrosis, capsular invasion, pT3a invasion pattern were identified as the significant predictors for RFS to establish the nomogram. The C-index of the nomogram was 0.753 (95% CI, 0.710-0.796) and 0.762 (95% CI, 0.701-0.822) for the training and validating group, respectively. The areas under the 1-year, 3-year and 5-year RFS receiver operating characteristic curves were 0.814, 0.769 and 0.768, respectively. Decision curve analysis showed the optimal application of the model in clinical decision-making. Patients with low risk T3a RCC have better RFS than those with high risk T3a RCC.

CONCLUSION

Tumor size, ISUP grade, necrosis, capsular invasion and T3a invasion patterns were independent risk factors for worse RFS in patients with nonmetastatic pT3a RCC. The current nomogram could effectively predict the RFS of patients with nonmetastatic pT3a RCC.

摘要

背景

建立一个列线图,以预测接受肾切除术的非转移性肾细胞癌(RCC)pT3a 期(pT3a)患者的术后无复发生存率(RFS)。

材料与方法

回顾性分析了 2008 年至 2019 年间 668 例 pT3a RCC 患者,随机分为训练组和验证组(比例为 7:3)。Cox 回归分析在训练组中建立了 RFS 预测列线图。使用 Harrell 一致性指数(C-index)、时间依赖性接收者操作特征曲线、决策曲线分析和 Kaplan-Meier 生存分析评估列线图的性能。

结果

在 668 例 pT3a RCC 患者中,有 167 例患者发生局部复发或远处转移。使用多变量 Cox 回归分析,肿瘤大小、ISUP 分级、坏死、包膜侵犯、pT3a 侵犯模式被确定为 RFS 的显著预测因素,建立了列线图。列线图的 C-index 在训练组和验证组中分别为 0.753(95%可信区间,0.710-0.796)和 0.762(95%可信区间,0.701-0.822)。1 年、3 年和 5 年 RFS 接收器工作特征曲线下面积分别为 0.814、0.769 和 0.768。决策曲线分析显示,该模型在临床决策中的最佳应用。低危 pT3a RCC 患者的 RFS 优于高危 pT3a RCC 患者。

结论

肿瘤大小、ISUP 分级、坏死、包膜侵犯和 T3a 侵犯模式是非转移性 pT3a RCC 患者 RFS 较差的独立危险因素。目前的列线图可以有效地预测非转移性 pT3a RCC 患者的 RFS。

相似文献

1
Development and Validation of a Nomogram for Predicting Postoperative Recurrence-Free Survival in Patients With Nonmetastatic Pathological T3a Stage Renal Cell Carcinoma.非转移性病理 T3a 期肾细胞癌患者术后无复发生存预测列线图的建立与验证。
Clin Genitourin Cancer. 2024 Dec;22(6):102196. doi: 10.1016/j.clgc.2024.102196. Epub 2024 Aug 12.
2
Development and validation of a nomogram to predict postoperative cancer-specific survival of patients with nonmetastatic T3a renal cell carcinoma.制定并验证一种列线图模型,以预测无远处转移 T3a 期肾细胞癌患者的术后癌症特异性生存情况。
Urol Oncol. 2021 Dec;39(12):835.e19-835.e27. doi: 10.1016/j.urolonc.2021.06.014. Epub 2021 Oct 4.
3
Development and validation of a nomogram to predict recurrence for clinical T1/2 clear cell renal cell carcinoma patients after nephrectomy.建立并验证一个列线图模型以预测 T1/T2 期肾透明细胞癌患者肾切除术后的复发风险。
BMC Surg. 2024 Jun 26;24(1):196. doi: 10.1186/s12893-024-02487-z.
4
[Predicting the 3-year tumor-specific survival in patients with T non-metastatic renal cell carcinoma].[预测T期非转移性肾细胞癌患者的3年肿瘤特异性生存率]
Beijing Da Xue Xue Bao Yi Xue Ban. 2024 Aug 18;56(4):673-679. doi: 10.19723/j.issn.1671-167X.2024.04.021.
5
Risk Factors for Upstaging, Recurrence, and Mortality in Clinical T1-2 Renal Cell Carcinoma Patients Upstaged to pT3a Disease: An International Analysis Utilizing the 8th Edition of the Tumor-Node-Metastasis Staging Criteria.8 版肿瘤-淋巴结-转移分期标准下临床 T1-2 期肾细胞癌患者升级为 pT3a 疾病的分期升级、复发和死亡的危险因素:国际分析利用
Urology. 2020 Apr;138:60-68. doi: 10.1016/j.urology.2019.11.036. Epub 2019 Dec 11.
6
[Establishment and validation of a novel nomogram to predict overall survival after radical nephrectomy].[一种预测根治性肾切除术后总生存期的新型列线图的建立与验证]
Zhonghua Zhong Liu Za Zhi. 2023 Aug 23;45(8):681-689. doi: 10.3760/cma.j.cn112152-20221027-00722.
7
Multi-institutional Survival Analysis of Incidental Pathologic T3a Upstaging in Clinical T1 Renal Cell Carcinoma Following Partial Nephrectomy.临床T1期肾细胞癌行部分肾切除术后偶然病理分期为T3a期的多机构生存分析
Urology. 2018 Jul;117:95-100. doi: 10.1016/j.urology.2018.04.002. Epub 2018 Apr 17.
8
A novel nomogram can predict pathological T3a upstaged from clinical T1a in localized renal cell carcinoma.一种新的列线图可以预测局限性肾细胞癌中从临床 T1a 升级为病理 T3a 的情况。
Int Braz J Urol. 2022 Sep-Oct;48(5):784-794. doi: 10.1590/S1677-5538.IBJU.2021.0859.
9
Predicting the prognosis of patients with renal cell carcinoma based on the systemic immune inflammation index and prognostic nutritional index.基于全身免疫炎症指数和预后营养指数预测肾细胞癌患者的预后。
Sci Rep. 2024 Oct 23;14(1):25045. doi: 10.1038/s41598-024-76519-2.
10
Impact of tumor size on patient survival after radical nephrectomy for pathological T3a renal cell carcinoma.肿瘤大小对 T3a 期肾癌根治性肾切除术后患者生存的影响。
Jpn J Clin Oncol. 2019 May 1;49(5):465-472. doi: 10.1093/jjco/hyy200.

引用本文的文献

1
Risk stratification for recurrence after nephrectomy in high-risk renal cell carcinoma patients.高危肾细胞癌患者肾切除术后复发的风险分层
Int J Clin Oncol. 2025 Jul 14. doi: 10.1007/s10147-025-02825-y.